



## CASE SERIES

Cà Granda Ospedale Maggiore Policlinico

Andrea Arighi

email  
[andrea.arighi@policlinico.mi.it](mailto:andrea.arighi@policlinico.mi.it)

18/06/2022

# 1 Case Series Description

**Age Range:** 31-98

**Size N:** 2181 subjects

**Recruitment:** from 2012 (10 years)

**Data collection:** from 2012 (10 years)

**Healthy controls:** yes (n: 24)

**Only at-risk gene carriers included:** no (n: 16)

**Diseases studied:**

Alzheimer Disease (AD) n: 715  
Subjective Cognitive Complaints (SCC) n: 191  
Mild Cognitive Impairment (MCI) n: 251  
Vascular Dementia (VaD) n: 135  
Frontotemporal Dementia (FTD) n: 228  
Lewy Bodies Dementia (DLB) n: 132  
Parkinson Disease (PD) n: 35  
Progressive Supranuclear Palsy (PSP) n: 18  
Corticobasal Degeneration (CBD) n: 23  
Creutzfeldt-Jakob Disease (CJD) n: 9  
Multiple System Atrophy (MSA) n: 2  
Primary Psychiatric Disorder n: 102  
Mixed dementia n: 265  
Normal Pressure Hydrocephalus n: 28  
Cerebral Amyloid Angiopathy n: 20  
Cerebral Amyloid Angiopathy related inflammation n: 2  
Huntington Disease n: 1

**Clinical Evaluation:**

- Neurological Assessment
- Neuropsychological Assessment
- Behavioural Assessment

**Imaging and Neurophysiology:**

- MRI 3 T (n: 782, 441 with advanced MRI sequences)
- FDG-PET (n: 721)
- Amyloid PET (n: 238)
- DaT SPECT (n: 71)

- Myocardial MIBG scintigraphy (n: 4)

#### **Genotyping:**

- ApoE for all, C9ORF72 for some, Next Generation Sequencing for some (NGS genes: APOE, APP, ATP13A2, ATP7B, C19ORF12, CHCHD10, CHMP2B, CP, CSF1R, DCTN1, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, FTL, FUS, GBA, GFAP, GRN, LRRK2, MAPT, MATR3, NOTCH3, NPC1, NPC2, PANK2, PFN1, PLA2G6, PRKAR1B, PRNP, PSEN1, PSEN2, SNCA, SORL1, SQSTM1, TARDBP, TBK1, TMEM230, TREM2, UBE3A, UBQLN2, VCP)

#### **Digital Data obtained from patients through electronic devices: no Biological Samples:**

- CSF n: 900
- DNA n: 900
- Plasma n: 900
- Serum n: 900

#### **Follow-up:**

- Number of Follow-ups planned: from 1 to 10
- Average duration between follow-ups (years): 0.5-1
- Follow-ups type: Clinical and Neuropsychological evaluation